ERBB2 and neoplasm: This has been attained through modification in the Fc region similar to margetuximab, a chimeric IgG1 anti-HER2 mAb [128], or with an antibody–drug conjugate (ADC) that covalently conjugates the tumor-specific mAb with a cytotoxin acting within the microtubules, thereby increasing antitumor immunity.